| ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lakeland Industries, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LAKE |
Globe Newswire |
03/28 |
19:36 |
| GSIT Investor News: If You Have Suffered Losses in GSI Technology Inc. (NASDAQ: GSIT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
03/28 |
19:36 |
| The Latest: Iranian-backed Houthi rebels claim responsibility for missile attacks on Israel |
AP Online |
03/28 |
19:12 |
| Crypto News of Last 24 Hours: Pepeto Crosses $8.47M While Bitcoin Price Targets $200K and Trump Family $1.2B Profits Reveal Where Insiders Are Moving |
Globe Newswire |
03/28 |
19:12 |
| HUBG Investor News: If You Have Suffered Losses in Hub Group, Inc. (NASDAQ: HUBG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
03/28 |
18:33 |
| DNOW Investor News: If You Have Suffered Losses in DNOW Inc. (NYSE: DNOW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
03/28 |
18:31 |
| Bills to pay FAA and TSA workers during shutdowns get introduced but keep stalling in Congress |
AP Online |
03/28 |
17:58 |
| The Man Who Called the Last Two Crashes Is Warning America Again — And This Time, He's Pointing at AI |
Globe Newswire |
03/28 |
17:00 |
| Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men |
Globe Newswire |
03/28 |
15:24 |
| MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting |
Globe Newswire |
03/28 |
15:00 |
| Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity |
Globe Newswire |
03/28 |
15:00 |
| New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis |
Globe Newswire |
03/28 |
15:00 |
| Gelatide Drops Under Investigation: Full Gelatide-1 Consumer Report Reveals Shocking Hidden Risks & Fake Gelatin Trick Recipe |
Globe Newswire |
03/28 |
14:58 |
| CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
03/28 |
14:12 |
| UFC brings cage-match bout to the White House, home of a president who favors cage-match politics |
AP Online |
03/28 |
14:03 |
| Software Engineering to Data Science Career Transition Guide 2026 Launched by Interview Kickstart |
Globe Newswire |
03/28 |
13:03 |
| ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages PayPal Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PYPL |
Globe Newswire |
03/28 |
12:54 |
| SonusZen Claims Evaluated: Testing the Legitimacy of Sonus Zen Formulation for Hearing Support |
Globe Newswire |
03/28 |
12:16 |
| HKIT Investor News: If You Have Suffered Losses in Hitek Global Inc. (NASDAQ: HKIT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
03/28 |
12:01 |
| FRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Freshpet, Inc. (NASDAQ: FRPT) Investors to Contact the Firm |
Globe Newswire |
03/28 |
12:00 |
| GDDY Investigation: Kessler Topaz Meltzer & Check, LLP Encourages GoDaddy Inc. (NYSE: GDDY) Investors to Contact the Firm |
Globe Newswire |
03/28 |
11:55 |
| SMCI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Super Micro Computer, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
Globe Newswire |
03/28 |
11:45 |
| Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting |
Globe Newswire |
03/28 |
11:00 |
| Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting |
Globe Newswire |
03/28 |
11:00 |
| Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session |
Globe Newswire |
03/28 |
11:00 |
